Insider Surge: Dogwood Therapeutics Executives Buy 330,000 Shares, Signaling Bullish Outlook Amid Volatile Stock Price
Insider buying spree at Dogwood Therapeutics shows executives bullish on its antiviral pipeline and partnership talks – could spark a rebound for investors.
3 minutes to read